These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 37766176)
1. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center. Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176 [TBL] [Abstract][Full Text] [Related]
2. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy. Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M Front Oncol; 2021; 11():686308. PubMed ID: 34820323 [TBL] [Abstract][Full Text] [Related]
3. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948 [TBL] [Abstract][Full Text] [Related]
4. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study. Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444 [TBL] [Abstract][Full Text] [Related]
7. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study. Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907 [TBL] [Abstract][Full Text] [Related]
8. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma. Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma. Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660 [TBL] [Abstract][Full Text] [Related]
10. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360 [TBL] [Abstract][Full Text] [Related]
11. Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma. Strum S; Climans S; Purcell V; Black M; Winquist E; Ernst S J Cutan Med Surg; 2024; 28(5):453-457. PubMed ID: 39056376 [TBL] [Abstract][Full Text] [Related]
12. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma. Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214 [No Abstract] [Full Text] [Related]
14. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel. Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S Front Oncol; 2023; 13():1117804. PubMed ID: 36793605 [TBL] [Abstract][Full Text] [Related]
15. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic. Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893 [TBL] [Abstract][Full Text] [Related]